Trial Profile

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elironrasib (Primary)
Indications Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors REVOLUTION Medicines

Most Recent Events

13 Jun 2024 Status changed from recruiting to active, no longer recruiting.
26 Feb 2024 According to a Revolution Medicines media release, the company continues dosing patients at 200 mg twice daily.
15 Feb 2024 Planned number of patients changed from 117 to 222.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com